Stemedica Cell Technologies, Inc., (“Stemedica”), a world leader in stem cell research and manufacturing, announced the signing of an agreement today for its breakthrough stem cell and related technology. The Jordanian Stem Cell Company has signed a five year multi-million dollar agreement to purchase the technology from Stemedica’s wholly-owned subsidiary, Stemedica International, S.A. The signing ceremony took place at the European Burns Association Congress in Lausanne, Switzerland.
“This is an important day for Stemedica International,” said Frank Schuller, PhD, Stemedica International’s Chairman. “This is a real testament to the quality and integrity of our products and the experience, dedication and professionalism of our team.” The signing ceremony was attended by Mr. Sam Alkhass, Chief Executive Officer of the Jordanian Stem Cell Company as well as several representatives from Stemedica, including Dr. Schuller; Mark Tager, MD, Executive for Stemedica’s Dermatological Operations; Alex Kharazi, MD, PhD, Stemedica’s Vice President for Research and Manufacturing; and, Riccardo Nisato, MBA, PhD, Director of Manufacturing and Business Development, Stemedica International S.A.
from http://www.reuters.com/article/pressRelease/idUS39335+07-Sep-2009+PRN20090907
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_c.png?x-id=7393bb3c-5bab-47b4-8f57-0953f1e5d5dc)
Maybe you can find something interesting in the following sponsored links:
0 Responses to “The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. First Clinical Trail Anticipated To Begin Early 2010”
Leave a Reply